C2N Diagnostics, LLC specializes in protein diagnostics and therapeutic discovery, utilizing advanced biomarker analysis to identify neurodegenerative diseases. The company focuses on providing precise diagnostic tools that enhance early detection and treatment options for conditions such as Alzheimer's disease.
Funding
$1.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Early and accurate diagnosis of neurodegenerative diseases, such as Alzheimer's, is challenging due to the subtle nature of initial symptoms and the limitations of current diagnostic methods. Traditional diagnostic approaches often involve invasive procedures or expensive imaging techniques, hindering widespread accessibility and early intervention.
Solution
C2N Diagnostics specializes in developing and commercializing advanced diagnostic solutions for neurodegenerative diseases, focusing on improving early detection and treatment decisions. The company leverages high-resolution mass spectrometry to identify and quantify critical protein biomarkers in blood, offering a less invasive and more accessible alternative to traditional methods. C2N's portfolio includes the Precivity™ line of blood tests, designed to assess brain amyloid pathology and aid healthcare providers in the diagnosis and management of Alzheimer's disease. These tests provide valuable insights into disease pathology, enabling timely medical management and treatment decisions. C2N also offers bioanalytical services to support clinical trials, accelerating the development of novel therapies for neurodegenerative disorders.
Target Audience
C2N Diagnostics serves healthcare providers, clinical researchers, and biopharmaceutical companies involved in the diagnosis, treatment, and study of Alzheimer's disease and related neurodegenerative disorders.
Features
- Proprietary liquid-chromatography-tandem mass spectrometry (LC-MS/MS) methodologies for precise biomarker analysis
- PrecivityAD® and PrecivityAD2™ blood tests to assess for brain amyloid pathology
- Precivity-ApoE™ blood test for apolipoprotein E2, E3, E4 allele status assessment
- SISAQ™ (Stable Isotope Spike Absolute Quantification) platform for measuring absolute peptide concentrations in biological fluids
- SILK™ (Stable Isotope Labeling Kinetic) platform for measuring protein production and clearance rates
- Comprehensive Brain Health Panel in development to measure multiple features of AD and other neurological disorders
- Bioanalytical services for clinical trials, including biomarker screening, monitoring, and customized data reporting